Prevalence and outcome of severe chronic obstructive pulmonary disease exacerbations caused by multidrug-resistant bacteria

Current Opinion in Pulmonary Medicine

Volumn 14, Issue 2, 2008, Pages 95-100

  Nseir, Saad ^a   Ader, Florence ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CROIX ROUSSE HOSPITAL   (France)

Author keywords

Acute exacerbation of chronic obstructive pulmonary disease; Inappropriate antibiotic treatment; Multidrug resistant bacteria; Ventilator associated pneumonia

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFTAZIDIME; CORTICOSTEROID; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; METICILLIN; MOXIFLOXACIN; OFLOXACIN;

ANTIBIOTIC THERAPY; BACTERIUM ISOLATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; ENDOTRACHEAL INTUBATION; HUMAN; INFECTION PREVENTION; LONG TERM CARE; LUNG FUNCTION; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; OUTCOME ASSESSMENT; PREVALENCE; REVIEW; RISK FACTOR; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-INFECTIVE AGENTS; BACTERIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; PNEUMONIA, VENTILATOR-ASSOCIATED; PREVALENCE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 40049093245     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3282f37a11     Document Type: Review

References (53)

1. Rivera-Fernandez R, Navarrete-Navarro P, Fernandez-Mondejar E, et al. Six-year mortality and quality of life in critically ill patients with chronic obstructive pulmonary disease. Crit Care Med 2006; 34:2317-2324. This multicenter study provides important data on mortality and quality of life of COPD patients after ICU admission.
2. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364:613-620.
3. Esteban A, Anzueto A, Frutos F, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 2002; 287:345-355.
4. Soler JJ, Martinez-GarciaMA, Roman P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60:925-931.
5. Sethi S. New developments in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease. Curr Opin Infect Dis 2004; 17:113-119.
6. Salgado CD, O'Grady N, Farr BM. Prevention and control of antimicrobial-resistant infections in intensive care patients. Crit Care Med 2005; 33:2373-2382.
7. Grundmann H, Barwolff S, Tami A, et al. How many infections are caused by patient-to-patient transmission in intensive care units? Crit Care Med 2005; 33:946-951.
8. Niederman M. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect Dis 2006; 42 (Suppl 2): S72-S81.
9. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
10. Evans HL, Lefrak SN, Lyman J, et al. Cost of Gram-negative resistance. Crit Care Med 2007; 35:89-95. The authors evaluate economic aspects of Gram-negative bacilli resistance in surgical ICU patients.
11. Nseir S, Di Pompeo C, Cavestri B, et al. Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: prevalence, risk factors, and outcome. Crit Care Med 2006; 34:2959-2966. This is the first large prospective study on prevalence, risk factors and outcome of severe COPD exacerbations related to multidrug-resistant bacteria.
12. Ewig S, Soler N, Gonzalez J, et al. Evaluation of antimicrobial treatment in mechanically ventilated patients with severe chronic obstructive pulmonary disease exacerbations. Crit Care Med 2000; 28:692-697.
13. Ferrer M, Ioanas M, Arancibia F, et al. Microbial airway colonization is associated with noninvasive ventilation failure in exacerbation of chronic obstructive pulmonary disease. Crit Care Med 2005; 33:2003-2009.
14. Lode H, Allewelt M, Balk S, et al. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection 2007; 35:143-149. Authors provide interesting data on risk factors for COPD exacerbations caused by enteric Gram-negative bacilli and Pseudomonas.
15. Lin SH, Kuo PH, Hsueh PR, et al. Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on Klebsiella pneumoniae and Pseudomonas aeruginosa. Respirology 2007; 12:81-87. Retrospective study providing data on etiology and outcome of COPD exacerbations in Taiwan.
16. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157:1498-1505.
17. Eller J, Ede A, Schaberg T, et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113:1542-1548.
18. Miravitlles M, Espinosa C, Fernandez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116:40-46.
19. Nseir S, Di Pompeo C, Brisson H, et al. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. Crit Care 2006; 10:R143. This study outlines the relationship between COPD and ICU-acquired S. maltophilia.
20. Pifarre R, Falguera M, Vicente-de-Vera C, Nogues A. Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med 2007; 101:2139-2144. This study compares characteristics and microbiology findings between COPD and non-COPD patients with community-acquired pneumonia.
21. Rello J, Rodriguez A, Torres A, et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006; 27:1210-1216. Comparison of patients with severe community-acquired pneumonia according to the presence or absence of COPD.
22. Monso E, Garcia-Aymerich J, Soler N, et al. Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect 2003; 131:799-804.
23. Zalacain R, Sobradillo V, Amilibia J, et al. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J 1999; 13:343-348.
24. Nseir S, Di Pompeo C, Soubrier S, et al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit Care Med 2005; 33:283-289.
25. Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Ann Intern Med 2001; 135:484-492.
26. Nseir S, Di Pompeo C, Diarra M, et al. Relationship between immunosuppression and intensive care unit-acquired multidrug-resistant bacteria: a case-control study. Crit Care Med 2007; 35:1318-1323. This is the first report on ICU-acquired multidrug-resistant bacteria in patients with severe immunosuppression.
27. Bauer TT, Torres A, Ferrer R, et al. Biofilm formation in endotracheal tubes. Association between pneumonia and the persistence of pathogens. Monaldi Arch Chest Dis 2002; 57:84-87.
28. Hanson LC, Weber DJ, Rutala WA. Risk factors for nosocomial pneumonia in the elderly. Am J Med 1992; 92:161-166.
29. Laaban JP. Nutrition and chronic respiratory failure. Ann Med Interne (Paris) 2000; 151:542-548.
30. Schaible UE, Kaufmann SH. Malnutrition and infection: complex mechanisms and global impacts. PLoS Med 2007; 4:e115. In this excellent review, the authors clearly discuss the pathophysiology of infection in patients with malnutrition.
31. Combes A, Luyt CE, Fagon JY, et al. Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med 2004; 170:786-792.
32. Zahar JR, Clec'h C, Tafflet M, et al. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia? Clin Infect Dis 2005; 41:1224-1231.
33. Nouira S, Marghli S, Belghith M, et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomized placebo-controlled trial. Lancet 2001; 358:2020-2025.
34. Wunderink RG. Radiologic diagnosis of ventilator-associated pneumonia. Chest 2000; 117:188S-190S.
35. Rammaert B, Ader F, Nseir S. [Mechanically ventilated acquired pneumonia and chronic obstructive pulmonary disease]. Rev Mal Respir (in press).
36. Basi SK, Marrie TJ, Huang JQ, Majumdar SR. Patients admitted to hospital with suspected pneumonia and normal chest radiographs: epidemiology, microbiology, and outcomes. Am J Med 2004; 117:305-311.
37. Lujan M, Gallego M, Fontanals D, et al. Prospective observational study of bacteremic pneumococcal pneumonia: effect of discordant therapy on mortality. Crit Care Med 2004; 32:625-631.
38. Nseir S, Di Pompeo C, Soubrier S, et al. Impact of ventilator-associated pneumonia on outcome in patients with COPD. Chest 2005; 128:1650-1656.
39. Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005; 33:2184-2193.
40. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26:1138-1180.
41. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Noninvasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. BMJ 2003; 326:185.
42. Girou E, Brun-Buisson C, Taille S, et al. Secular trends in nosocomial infections and mortality associated with noninvasive ventilation in patients with exacerbation of COPD and pulmonary edema. JAMA 2003; 290:2985-2991.
43. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347:465-471.
44. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 2:CD004403. Interesting meta analysis of 11 randomized trials including more than 900 patients.
45. Wilson R. Treatment of COPD exacerbations: antibiotics. Eur Respir Rev 2005; 14:32-38.
46. Niederman MS. Who should receive antibiotics for exacerbations of chronic bronchitis? A plea for more outcome-based studies. Clin Infect Dis 2004; 39:987-989.
47. Cameron RJ, de Wit D, Welsh TN, et al. Virus infection in exacerbations of chronic obstructive pulmonary disease requiring ventilation. Intensive Care Med 2006; 32:1022-1029. This study provides important data on the role of viral infection in severe COPD exacerbations using the PCR technique.
48. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131:9-19. This large randomized trial demonstrates the possibility of reducing antibiotic use in COPD exacerbations without negative impact on outcome.
49. Van der Valk P, Monninkhof E, Van der Palen J, et al. Clinical predictors of bacterial involvement in exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis 2004; 39:980-986.
50. 1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167:1090-1095.
51. Burge PS, Calverley PM, Jones PW, et al. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-1303.
52. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789. Strong data from a large randomized trial on the impact of inhaled corticosteroids on outcome of patients with exacerbated COPD.
53. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176:162-166. This large nested case-control study outlines an important infectious side effect of inhaled corticosteroids in COPD patients.